Business Wire

NTT-LTD.

18.5.2023 14:01:25 CEST | Business Wire | Press release

Share
NTT and Cisco Launch IoT as-a-Service for Enterprise Customers

NTT Ltd., a leading IT infrastructure and services company, and Cisco, a worldwide leader in technology, today announced a collaboration to develop and deploy joint solutions that empower organizations to improve operational efficiencies and advance sustainability goals.

Leveraging NTT’s Edge as a Service portfolio and Cisco’s IoT capabilities, solutions developed by the two companies will offer real-time data insights, enhanced security, improved decision-making, and reduced operational costs through predictive maintenance, asset tracking, and supply chain management capabilities.

The companies will deliver solutions that combine NTT’s Managed Services expertise, automation capabilities at the edge, and the management of complex IT environments, with Cisco’s IoT capabilities, including Low Power Wide Area Networking (LoRaWAN).

As part of today’s news, NTT has bolstered its IoT consulting and services business that brings together more than 1000 practitioners and 100 use cases in areas such as connected cars, fleet management, predictive maintenance, smart cities, digital twins, connected factories, utilities and more. NTT has already trained more than 500 Cisco sales experts to accelerate the companies’ combined capabilities and go-to-market efforts.

“We are accelerating our IoT business initiatives to deliver a powerful portfolio of repeatable services that can be tailored to meet customer demand for these kinds of solutions. We’re in a unique position,” said Devin Yaung, SVP of Group Enterprise IoT Products and Services at NTT.

“We are excited to work together to help transition our customers to this IoT-as-a-Service model so they can quickly realize the business benefits across industries and around the globe,” said Samuel Pasquier, VP of Product Management, Industrial IoT Networking, Cisco.

Transforming Water Management Through Smart Solutions

NTT and Cisco are developing solutions and go-to-market offers focusing on industries such as manufacturing, transportation, and healthcare, where there is a growing demand for edge computing and IoT solutions. The two companies are already deploying this advanced ‘ruggedized’ service to several customers including Compagnie Intercommunale Liégeoise des Eaux (CILE), a public water distribution company located in Belgium.

NTT and Cisco have deployed thousands of LoRaWAN sensors across CILE’s infrastructure to provide remote visibility that improves operational efficiencies related to water quality, consumption, distribution, and maintenance. The solution also includes advanced technologies such as smart distribution networks, remote reading through smart meters, smart grid for remote management, connected IoT objects, and AI, delivered as a managed service. The network also provides the building blocks to support other sustainability use cases such as waste management, parking management, water quality and street light controls.

“At CILE, we provide critical infrastructure for 24 cities in Belgium, which means efficiency, security and reliability are key," said William de Angelis, CIO and CDO at CILE. “With NTT and Cisco’s support, we have real-time insights into our facilities and distribution networks, including faster detection of leaks, allowing us to respond to issues instantaneously and expand the network to other sustainability use cases.”

NTT Ramps Up IoT Consulting and Services Business

In a move to prioritize and scale IoT for clients and partners, NTT has activated an IOT-dedicated business unit bringing together deep expertise and capabilities from around the globe. The team of 1,000 consultants, engineers, enterprise architects, and sustainability experts will build, deploy, and manage more than 100 use cases in areas such as connected cars, fleet management, predictive maintenance, smart cities, digital twins, connected factories and more.

“We’re doubling down on NTT’s IoT capabilities to meet customer demand,” continued Yaung. “What we’re doing is pulling together our collective knowledge and skillsets, and putting the full power of NTT behind it, to better service our customers and the increasing need to outfit or retrofit their organizations with the connectivity and visibility they need to improve day-to-day business operations.”

The global IoT market is expected to grow 19 percent in 2023, with a potential market size of $483 billion by 2027.

#ENDS#

About NTT Ltd.
As part of NTT DATA, a USD 30 billion IT services provider, NTT Ltd. is a leading IT infrastructure and services company serving 65% of the Fortune Global 500 and more than 75% of the Fortune Global 100. We lay the foundation for organizations’ edge-to-cloud networking ecosystem, simplify the complexity of their workloads across multicloud environments, and innovate at the edge of their IT environments where networks, cloud and applications converge. We offer tailored infrastructure and ensure consistent best practices in design and operations across all of our secure, scalable and customizable data centers. On the journey towards a software-defined future, we support organizations with our platform-delivered infrastructure services. We enable a connected future.

Visit us at services.global.ntt

About Cisco
Cisco (NASDAQ: CSCO) is the worldwide leader in technology that powers the Internet. Cisco inspires new possibilities by reimagining your applications, securing your data, transforming your infrastructure, and empowering your teams for a global and inclusive future. Discover more on The Newsroom and follow us on Twitter at @Cisco.

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005431/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release

Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye